Germany
Complement Therapeutics, founded in 2020, is a biotechnology company dedicated to pioneering the development of the next generation of complement medicines. Headquartered in Germany, this spinout from the University of Manchester focuses on innovative therapeutics for complement-mediated diseases.
Their lead candidate, CTx001, is under evaluation as a gene therapy for Geographic Atrophy (GA), a major cause of blindness among the elderly. With research labs in Stevenage, UK, and subsidiaries in the UK and USA, Complement Therapeutics is strategically positioned for broad international research and development.
In a recent Series A funding round, the company secured €72.00M from prominent investors including BioGeneration Ventures, Forbion, Cambridge Innovation Capital, GIMV, Hadean Partners, Panakes Partners, and Seroba Life Sciences. This investment reflects strong confidence in its potential to address significant unmet clinical needs in the field of biotechnology.
Beacon Therapeutics